Director, Omnichannel Strategy, Medical Affairs
![]() | |
![]() United States, Massachusetts, Cambridge | |
![]() 45 Sidney Street (Show on map) | |
![]() | |
How will your role help us transform hope into reality? Are you ready to lead the charge in transforming how we engage with our health care providers? Blueprint Medicines is seeking an innovative Director of Omnichannel Strategy to join our Medical Affairs team during an exciting period of tremendous growth. With our leading expertise in mast cell diseases, this role is critical in shifting to a customer-centric model in targeting and moving beyond a platform-focused approach. You will be instrumental in building and executing our omnichannel and digital strategy by leading the strategic planning, development, and execution of omnichannel scientific communications tactics and sponsored medical education initiatives for the Medical Affairs team. This role involves close collaboration across Medical Affairs, including Medical Directors, Scientific Communications & Publications, Field Medical, and Medical Operations as well as cross functional partners in commercial, corporate communications, and program management. With a pipeline full of promising developments, your expertise will also help us prepare for the future. Currently reporting to the SVP, Medical Affairs, you will have the opportunity to shape and define the omnichannel medical landscape at Blueprint Medicines, setting new standards for customer engagement and experience. What will you do? Set and Build Omnichannel Strategy:
Customer Experience Optimization:
Data-Driven Decision Making:
Content Development and Consistency:
Training and Support:
Budget and Resource Management:
What minimum qualifications do we require?
What additional qualifications will make you a stronger candidate?
Why Blueprint? At Blueprint Medicines, we achieve impactful results because of our global crew of compassionate innovators - the Blue Crew. Through authentic relationships and our collective entrepreneurial spirit and action, we are each empowered to take ownership and execute with strategic prioritization. We put trust in our people to break through norms and conventions using their individual strengths and insights, which drives our success. This is the place where the extraordinary becomes reality, and you could be part of it. Patients are waiting. Are you ready to make the leap? Equity, Diversity, Inclusion and Affirmative Action At Blueprint Medicines, we foster a culture of equity, diversity and inclusion. A proud Equal Employment Opportunity and Affirmative Action employer, we consider all qualified applicants without regard to race, color, sex, gender identity or expression, sexual orientation, age, religion, national origin, ancestry, ethnicity, disability, veteran status, genetic information, or any other characteristic protected under applicable law. We are also an E-Verify Employer. We will make reasonable accommodations, absent undue hardship, for qualified individuals with known disabilities. If you are an individual with a disability in need of an accommodation with the application or recruiting process, please reach out to TotalRewards@blueprintmedicines.com. For more information, please see ourEEO-AA Policy Statement, the E-Verify Participation Poster, the Right to Work Poster, and/or theEEO Know Your Rights Poster, as well as ourPay Transparency Statement. Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a proven track record of success with two approved medicines, including bringing our medicine to patients with systemic mastocytosis (SM) in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including SM and chronic urticaria, breast cancer and other solid tumors. #LI-Hybrid #LI-AQ1 |